Bile acid synthesis defect, congenital, 1
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
Bile acid synthesis defect, congenital, 1
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease.
|
12679481 |
2003 |
Bile acid synthesis defect, congenital, 1
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease.
|
12679481 |
2003 |
Bile acid synthesis defect, congenital, 1
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease.
|
12679481 |
2003 |
Bile acid synthesis defect, congenital, 1
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis.
|
11067870 |
2000 |
Bile acid synthesis defect, congenital, 1
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis.
|
11067870 |
2000 |
Bile acid synthesis defect, congenital, 1
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Bile acid synthesis defect, congenital, 1
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Bile acid synthesis defect, congenital, 1
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Bile acid synthesis defect, congenital, 1
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Cholestasis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships.
|
25526675 |
2015 |
Cholestasis, progressive familial intrahepatic 4
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Corpuscular Hemoglobin Concentration Mean
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Seventy-five genetic loci influencing the human red blood cell.
|
23222517 |
2012 |
Blood Coagulation Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Intrahepatic Cholestasis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Diarrhea
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Failure to Thrive
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Gastrointestinal Hemorrhage
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hepatomegaly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hyperbilirubinemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Icterus
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Malabsorption Syndrome
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Neonatal hepatitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Nyctalopia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Osteoporosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|